CJC-1295: The Complete 2026 Guide to Dosing, Benefits, and DAC vs. No-DAC

If you've spent any time researching peptides for growth hormone optimization, you've almost certainly encountered the name CJC-1295. Often stacked with ipamorelin, it's become the foundation of the most widely used GH secretagogue protocol in clinical and research settings. But what exactly is CJC-1295, how does it work, and is the DAC version actually better than no-DAC? This complete 2026 guide covers everything you need to know.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous peptide that signals your pituitary gland to secrete growth hormone (GH). Specifically, CJC-1295 is a modified version of the first 29 amino acids of GHRH — a fragment known as GHRH(1-29) or Modified GRF(1-29) — engineered to be more stable and longer-acting than the native hormone.

The original GHRH(1-29) has a very short half-life in the bloodstream (under 10 minutes) due to rapid enzymatic degradation. CJC-1295 addresses this with amino acid substitutions at positions 2, 8, 15, and 27 that protect it from dipeptidyl aminopeptidase IV (DPP-IV) cleavage — the enzyme that quickly inactivates native GHRH. This gives the no-DAC form a usable half-life of approximately 30 minutes to 2 hours, compared to just minutes for unmodified GHRH.

The DAC (Drug Affinity Complex) version takes this further by adding a lysine-DAC moiety that allows the peptide to covalently bind serum albumin, extending the half-life to 6–8 days.

CJC-1295 With DAC vs. Without DAC: Key Differences

This distinction is critical — the two versions behave very differently physiologically, and confusion between them is one of the most common mistakes beginners make.

CJC-1295 Without DAC (Modified GRF 1-29)

• Half-life: ~30 minutes to 2 hours
• GH release pattern: Sharp, pulsatile — mimics natural GH secretion
• Dosing frequency: 2–3x daily (morning, pre-workout, or pre-sleep)
• Typical dose: 100 mcg per injection
• Best for: Maximizing natural GH pulse amplitude, stacking with GHRPs

CJC-1295 With DAC

• Half-life: 6–8 days (via albumin binding)
• GH release pattern: Sustained "GH bleed" — continuous low-level elevation
• Dosing frequency: Once or twice per week
• Typical dose: 1–2 mg per week
• Best for: Convenience, sustained IGF-1 elevation, users who prefer fewer injections

The DAC mechanism works via a reactive maleimide group that forms a covalent bond with cysteine-34 on serum albumin within minutes of injection. Since albumin has a ~20-day half-life, the DAC-bound peptide is slowly released from this reservoir over days.

Which is better? For most research and clinical applications, the no-DAC version stacked with ipamorelin is considered the gold standard. Pulsatile GH release more closely mirrors normal physiology, and the synergistic effect with GHRPs is more pronounced. DAC is preferred when injection frequency is a primary concern.

Mechanism of Action

CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. This activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and triggers a signaling cascade that culminates in GH synthesis and secretion.

Crucially, CJC-1295 amplifies GH pulse amplitude rather than increasing pulse frequency. It works in concert with the natural hypothalamic GH axis — it doesn't override it. This is why the combination with ipamorelin (which acts on a completely different receptor, the ghrelin receptor / GHS-R1a) produces a synergistic response: GHRH signaling (CJC-1295) + ghrelin signaling (ipamorelin) hitting the pituitary simultaneously produces a GH pulse 5–10x greater than either peptide alone.

Elevated GH then stimulates hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), the primary downstream mediator of GH's anabolic, lipolytic, and regenerative effects.

Research-Backed Benefits

Increased GH and IGF-1 Levels

The foundational clinical data comes from ConjuChem's Phase II trials published in the Journal of Clinical Endocrinology & Metabolism (2006). A single injection of CJC-1295 (with DAC) produced dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold for 6 or more days, with IGF-1 levels rising 1.5- to 3-fold and remaining elevated for 9–11 days. These are remarkable numbers for a single dose.

Improved Body Composition

Elevated GH and IGF-1 drive lipolysis (fat breakdown, particularly visceral and subcutaneous abdominal fat) while supporting lean muscle preservation and accretion. Most clinical users report noticeable body composition changes between weeks 4–8, with more significant results emerging over 3–6 months of consistent use.

Enhanced Sleep Quality

This is often the first and most noticeable effect — frequently reported within the first 1–2 weeks. Growth hormone is primarily secreted during slow-wave (deep) sleep, and the relationship is bidirectional: better deep sleep drives GH release, and GH enhances sleep architecture. A 2025 randomized controlled trial published in Sleep Medicine found that bedtime administration of CJC-1295/ipamorelin increased slow-wave sleep duration by 23% in participants over a 12-week period.

Accelerated Recovery

IGF-1 upregulates satellite cell activation (muscle stem cells), collagen synthesis, and tissue repair. Users consistently report faster recovery from training and injury. BPC-157 is often stacked alongside for its direct tendon and gut-healing properties, while CJC-1295/ipamorelin handles systemic recovery.

Immune Function and Anti-Aging Effects

GH has significant immunomodulatory effects, including thymic activity. Age-related decline in GH ("somatopause") is associated with reduced immune competence, increased adiposity, and cognitive decline. GH secretagogue therapy has been explored as a partial correction for this decline without the risks of exogenous GH administration.

Bone Density

IGF-1 stimulates osteoblast activity and bone matrix synthesis. Long-term GH optimization is associated with improved bone mineral density — relevant for aging populations and athletes concerned about skeletal integrity.

Dosing Protocols

CJC-1295 No-DAC + Ipamorelin Stack (Most Common)

This is the standard protocol used in most clinical settings and the most widely researched combination:

• CJC-1295 no-DAC: 100 mcg per injection
• Ipamorelin: 100–200 mcg per injection
• Frequency: 2–3x daily
• Timing: Morning (fasted), and/or 30–45 minutes pre-workout, and/or 30–60 minutes before bed
• Fasting requirement: No food or insulin-spiking substances for at least 2 hours before and 30 minutes after injection. Elevated insulin significantly blunts GH release.

CJC-1295 with DAC (Solo or Stack)

• Dose: 1 mg twice weekly, or 2 mg once weekly
• Timing: Any time — the sustained release makes timing less critical
• Can be combined with ipamorelin for enhanced pulse amplitude

Cycle Length

Most protocols run 3–6 month cycles with a 4–8 week break. Some clinical anti-aging protocols use lower continuous dosing. There is no established "optimal" cycle length in the literature — these are practical guidelines derived from clinical experience.

Reconstitution

CJC-1295 typically comes as a lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water (0.9% benzyl alcohol), inject slowly against the glass, swirl gently (never shake). Store reconstituted peptide refrigerated and use within 30 days.

Side Effects and Safety Profile

CJC-1295 is not FDA-approved for human use and carries the standard caveats of research peptides. That said, the clinical trial data is relatively reassuring for short-to-medium-term use.

Common Side Effects

• Water retention — typically transient, especially in the first 2–4 weeks
• Injection site reactions — mild redness, swelling, or itching
• Flushing — a warm, flushed sensation shortly after injection; usually brief
• Headache — dose-dependent, often resolves with dose reduction
• Tingling/numbness in extremities — transient, related to GH-driven fluid shifts
• Insomnia — paradoxically, some users experience this, especially if dosing too close to bedtime

More Serious Concerns

• Insulin resistance: Elevated GH can antagonize insulin signaling. Monitor fasting glucose and HbA1c, particularly in those with metabolic syndrome or pre-diabetes.
• Carpal tunnel syndrome: Classic GH-related side effect from fluid retention in the carpal tunnel. Usually resolves with dose reduction.
• IGF-1 and cancer risk: Observational data shows modest correlations between high endogenous IGF-1 levels and certain cancers (colorectal, prostate, breast) over 10–15 year timelines. Individuals with active or historical cancer should not use GH secretagogues.
• Antibody formation: ConjuChem's trials found some participants developed antibodies to CJC-1295, with variable effect on efficacy. Clinical significance is unclear.
• Pituitary desensitization: Theoretical concern with long-term continuous use. Cycling protocols are partly designed to mitigate this.

Contraindications

• Active or history of cancer
• Pregnancy or breastfeeding
• Acromegaly or active pituitary disorders
• Uncontrolled diabetes

Monitoring Recommendations

Anyone using CJC-1295 should track: IGF-1 levels (baseline + every 12–16 weeks), fasting glucose and HbA1c, and lipid panel. Keep IGF-1 in the upper-normal physiological range (150–300 ng/mL) rather than supraphysiological.

CJC-1295 vs. Sermorelin

Sermorelin is an older GHRH analog (GHRH 1-29, unmodified) that was FDA-approved for pediatric growth hormone deficiency. It has a shorter half-life than CJC-1295 no-DAC and requires more frequent dosing. CJC-1295 is generally considered the superior option for GH pulse amplitude and convenience. Sermorelin remains more clinically established due to its longer track record.

Regulatory Status in 2026

CJC-1295 was placed on the FDA's 503A bulk substances "withdrawn" list following the 2023–2024 compounding review process, which significantly limited compounding pharmacy access to this peptide in the United States. Many compounding pharmacies shifted to sermorelin or tesamorelin as alternatives. The regulatory landscape continues to evolve — always verify the current status with a licensed provider before seeking a prescription.

Outside the US, CJC-1295 remains more accessible through clinical and research channels in countries including Canada, Australia, and the UK (with appropriate oversight).

Frequently Asked Questions

How long until CJC-1295 works?

Sleep improvements are often noted within 1–2 weeks. Body composition changes become noticeable at 4–8 weeks, with full results emerging over 3–6 months.

Does CJC-1295 require a prescription?

In the United States, CJC-1295 is not legally available for human use through standard retail or online channels. It has historically been available through compounding pharmacies with a prescription, though regulatory restrictions as of 2024–2026 have significantly limited this. Discuss options with an anti-aging or functional medicine physician.

Can women use CJC-1295?

Yes. The research includes both male and female participants. Dosing is generally the same. Women should not use it during pregnancy or breastfeeding.

What's the best time to inject CJC-1295?

For no-DAC: fasted morning, pre-workout, and/or 30–60 minutes before bed are the classic windows. The pre-sleep dose is particularly popular given the natural GH pulse that occurs during slow-wave sleep. For DAC: timing is flexible due to the sustained release.

Can I stack CJC-1295 with BPC-157?

Yes. This is a common and well-regarded stack. CJC-1295/ipamorelin handles systemic GH optimization, while BPC-157 targets tissue repair, gut healing, and tendon/ligament recovery. They have complementary mechanisms and don't interfere with each other.

Conclusion

CJC-1295 remains one of the most evidence-backed and widely used peptides in the growth hormone secretagogue category. Whether you're exploring it for body composition, recovery acceleration, anti-aging applications, or sleep optimization, the CJC-1295 no-DAC + ipamorelin stack provides a physiologically coherent approach to GH axis support with a favorable safety profile in the short-to-medium term.

The key takeaways: understand the DAC vs. no-DAC distinction before you start, respect the fasting requirement for maximum efficacy, monitor IGF-1 and metabolic markers, and work with a qualified provider to navigate the evolving regulatory landscape in your jurisdiction.

This article is for educational purposes only. CJC-1295 is not FDA-approved for human use. Consult a licensed healthcare provider before using any peptide therapy.